Cited by 887Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and DiagnosticsAcute Myocardial Infarction Research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

Open access

Collet, Jean-Philippe, Cuisset, Thomas, Rangé, Grégoire, Cayla, Guillaume, Elhadad, Simon, Pouillot, Christophe, Henry, Patrick, Motreff, Pascal, Carrié, Didier, Boueri, Ziad, Belle, Loic, Van Belle, Eric, Rousseau, Hélène, Aubry, Pierre, Monségu, Jacques, Sabouret, Pierre, O'Connor, Stephen A., Abtan, Jérémie, Kerneis, Mathieu, Saint-Etienne, Christophe, Barthélémy, Olivier, Beygui, Farzin, Silvain, Johanne, Vicaut, Eric, Montalescot, Gilles·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1209979

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy. METHODS: We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment in patients who had a poor response to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment. The primary end point was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 year after stent implantation. For patients in the monitoring group, the VerifyNow P2Y12 and aspirin point-of-care assays were used in the catheterization laboratory before stent implantation and in the outpatient clinic 2 to 4 weeks later. RESULTS: In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an additional bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure. The primary end point occurred in 34.6% of the patients in the monitoring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval [CI], 0.98 to 1.29; P=0.10). The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional-treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P=0.77). The rate of major bleeding events did not differ significantly between groups. CONCLUSIONS: This study showed no significant improvements in clinical outcomes with platelet-function monitoring and treatment adjustment for coronary stenting, as compared with standard antiplatelet therapy without monitoring. (Funded by Allies in Cardiovascular Trials Initiatives and Organized Networks and others; ARCTIC ClinicalTrials.gov number, NCT00827411.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1209979

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation
Guidelines on myocardial revascularization
Wijns, W. C., Kolh, P. H., Danchin, N., Mario, C. D., Falk, V., Folliguet, T. A., Garg, S., Huber, K., James, S. K., Knuuti, J., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq277 · Cited by 3,228
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention
Price, M. J. (2011) · JAMA · doi:10.1001/jama.2011.290 · Cited by 1,311
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D. J., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,158
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Bonello, L., Tantry, U. S., Marcucci, R., Blindt, R., Angiolillo, D. J., Becker, R. C., Bhatt, D. L., Cattaneo, M., Collet, J., Cuisset, T., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.047 · Cited by 1,151
Self-citation
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation
Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J. T., Bal, E. T., Deneer, V. H. M., Harmsze, A. M., der Heyden, J. A. S. V., Rensing, B. J. W. M., et al. (2010) · JAMA · doi:10.1001/jama.2010.181 · Cited by 850
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
Mehta, S. R., Tanguay, J., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H., Budaj, A., Avezum, Á., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61088-4 · Cited by 812
Self-citation
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citation

Flagged first, then by citations

Show all 26 references

Sorted by citations

Items 601–700 of 883

Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction
Coons, J. C., Schwier, N. C., Harris, J. R., & Seybert, A. L. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.890589 · Cited by 4
Prasugrel hydrochloride for the treatment of acute coronary syndromes
Lhermusier, T., & Waksman, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1005602 · Cited by 4
ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS?
Grinshtein, Y. I., Александровна, К. А., & Grinshtein, Y. I. (2013) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2013-9-6-682-689 · Cited by 4
Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention
Li, Q., Li, M., Yu, X., He, J., Gao, Y., Zhang, X., Wu, C., Luo, Y., Zhang, Y., & Ren, X. (2017) · Coronary Artery Disease · doi:10.1097/mca.0000000000000512 · Cited by 4
Benefits of laboratory personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
Zhang, Y., Zhang, P., Zhan, L., Du, J., Wang, J., Tian, X., Gao, M., & Hou, Y. (2017) · Cardiology Journal · doi:10.5603/cj.a2017.0127 · Cited by 4
Monitoring of biological response to clopidogrel after treatment for non-cardioembolic ischemic stroke or transient ischemic attack.
Varvat, J., Montmartin, A., Epinat, M., Accassat, S., Garcin, A., Li, G., Garnier, P., Lambert, C., Mismetti, P., & Mallouk, N. (2019) · PubMed Central · Cited by 4
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study)
Faggioni, M., Redfors, B., Crowley, A., Claessen, B. E. P. M., Farhan, S., Mastoris, I., Witzenbichler, B., Maehara, A., Weisz, G., Généreux, P., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.11.033 · Cited by 4
Use of Thromboelastography Platelet Mapping for Assessment of Individual Platelet Response Secondary to Oral Antiplatelet Therapy after Percutaneous Coronary Intervention: An Attempt to Start Personalized Antiplatelet Therapy in India
Datta, S. S., De, D., & Muslim, N. A. (2021) · Journal of Cardiac Critical Care TSS · doi:10.1055/s-0041-1735667 · Cited by 4
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China
Lyu, S., Zhu, J., Wang, J., Wu, S., Zhang, H., Shao, X., & Yang, Y. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03224-8 · Cited by 4
Klinische Pharmakologie der aktuellen antithrombozytären Substanzen
Trenk, D., Nührenberg, T. G., Stratz, C., Valina, C. M., & Hochholzer, W. (2014) · Herz · doi:10.1007/s00059-014-4151-9 · Cited by 4
Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors
Howell, L. A., Stouffer, G. A., Polasek, M. J., & Rossi, J. S. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1057571 · Cited by 4
Monitoring Persistent Platelet Reactivity in Patients with Unprotected Left Main Stenting
Dillinger, J., Sidéris, G., KCHAOU, I., Sollier, C. B. D., Manzo‐Silberman, S., Voicu, S., Magkoutis, N. A., Logeart, D., Drouet, L. O., Henry, P., et al. (2013) · Journal of Interventional Cardiology · doi:10.1111/joic.12076 · Cited by 4
Self-citation
Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes
Ismail, S. J., Lee, Y. M., Patel, M., Duarte, J. D., & Ardati, A. K. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.970180 · Cited by 4
CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel
Rodríguez‐González, F., Martínez‐Quintana, E., Saavedra, P., Medina-Gil, J. M., Riaño, M., Garay‐Sánchez, P., & Tugores, A. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1144 · Cited by 4
P2Y12 Antagonists
Cattaneo, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00051-5 · Cited by 5
Prasugrel
Serebruany, V. L., & Atar, D. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000239 · Cited by 4
Personalised antiplatelet therapy: are we ready for prime time? Data from China
Li, J., & Huo, Y. (2013) · EuroIntervention · doi:10.4244/eijv9i3a49 · Cited by 4
CYP2C19 Genotyping in Percutaneous Coronary Intervention-Treated Patients
Sibbing, D., & Groß, L. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.08.041 · Cited by 4
Are Patients Getting Their Aspirin's Worth in Ischemic Stroke?
Schmaier, A. A., & Bhatt, D. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009564 · Cited by 4
When to Believe Unexpected Results for Ticagrelor or Prasugrel
Bittl, J. A., Yong, C. M., & Sharma, G. V. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.08.012 · Cited by 4
Dual antiplatelet therapy escalation and de-escalation
Greco, A., Leo, G. D., Finocchiaro, S., Imbesi, A., & Capodanno, D. (2026) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf173 · Cited by 3
High On-Treatment Platelet Reactivity in Patients Undergoing Complex Percutaneous Coronary Interventions
Urban, L., Škorňová, I., Žolková, J., Staško, J., Bolek, T., & Samoš, M. (2023) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296231199089 · Cited by 3
Personalized antiplatelet therapy: The wrong approach?
Collet, J., & Montalescot, G. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.08.001 · Cited by 3
Self-citation
Laboratory Control of Anticoagulant, Thrombolytic and Antiplatelet Therapy
Laffan, M., & Manning, R. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6696-2.00020-5 · Cited by 3
Tests d’évaluation de la fonction plaquettaire délocalisés : un guide pour la transfusion de plaquettes ?
Bonhomme, F. (2016) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2016.08.001 · Cited by 3
Thrombose de stent : quoi de neuf en 2017 ?
Kallel, R., Hakim, R., & Rangé, G. (2017) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2017.10.007 · Cited by 3
Self-citation
Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction
Ikeda, Y., Yamanouchi, J., Kumon, Y., Yasukawa, M., & Hato, T. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.10.003 · Cited by 3
Indicación del tratamiento con doble antiagregación más allá del año. A quién y por qué
Gómez-Polo, J. C., Vivas, D., & Roldán, I. (2017) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(19)30020-2 · Cited by 3
Laboratory Monitoring of Antiplatelet Therapy
Gremmel, T., Bhatt, D. L., & Michelson, A. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00036-9 · Cited by 5
Precision Treatment in ACS–Role of Assessing Fibrinolysis
Gue, Y. X., Jeong, Y., Farag, M., Spinthakis, N., & Gorog, D. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050929 · Cited by 3
An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention
Wang, J., Wang, J., Dong, Z., Ma, J., Teng, J., Wang, T., Zhang, X., Gu, Q., Ye, Z., Ullah, I., et al. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00323-5 · Cited by 3
The influence of acute coronary syndrome on the levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19 and ABCB1 gene polymorphisms
Wójcik, T., Karolko, B., Wiśniewski, J. Ł., Mysiak, A., Ściborski, K., Onisk, G., Lebioda, A., Jonkisz, A., & Protasiewicz, M. (2021) · Advances in Interventional Cardiology · doi:10.5114/aic.2021.106894 · Cited by 3
Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status
Cavallari, I., Patti, G., Maddaloni, E., Veneziano, F. A., Mangiacapra, F., Ricottini, E., Buzzetti, R., Ussia, G. P., & Grigioni, F. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.01.057 · Cited by 3
Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study
Mathew, R. O., Sidhu, M. S., Rihal, C. S., Lennon, R. J., El-Hajjar, M. C., Yager, N., Lyubarova, R., Abdul-Nour, K., Weitz, S., O'Cochlain, D. F., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07392-2 · Cited by 3
Guided vs. conventional anti-platelet therapy for patients with acute coronary syndrome: A meta-analysis of randomized controlled trials
Zhong, P.-Y., Deng, J.-P., Zhao, J., Peng, L., Liu, T., & Wang, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1079332 · Cited by 3
Efficacy and safety of ticagrelor monotherapy following a brief DAPT vs. prolonged 12-month DAPT in ACS patients post-PCI: a meta-analysis of RCTs
Qamar, U., Naeem, F., Maqsood, M. T., Khan, M. Z., Imtiaz, Z., Saeed, F. O., Gupta, N., Brohi, F. Z., Mkpozi, C., & Sattar, Y. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03747-w · Cited by 3
Optimising pharmacotherapy for secondary prevention of non‐invasively managed acute coronary syndrome
Thompson, P. L., Thompson, A., & Judkins, C. (2014) · The Medical Journal of Australia · doi:10.5694/mja14.01155 · Cited by 3
Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
Zeymer, U., Montalescot, G., Ardissino, D., Bolognese, L., Clemmensen, P. M., Collet, J., Lopez-Sendon, J. L., & Widimský, P. (2015) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872615584076 · Cited by 3
Self-citation
Acute myocardial infarction occurring while on chronic clopidogrel therapy (‘clopidogrel failure’) is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis
Regev, E., Asher, E., Fefer, P., Beigel, R., Mazin, I., Matetzky, S., & For The Platelets and Thrombosis in Sheba (PLATIS) - Study Group (2018) · PLoS ONE · doi:10.1371/journal.pone.0195504 · Cited by 3
Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting
Feng, Z.-M., Lin, Y.-Q., Deng, B., Shu, X., Ke, X., & Nie, R. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108773 · Cited by 3
Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity
Schneider, D. J., Honda, T., Feldmann, E. G., de Havenon, A., Romano, J. G., Nogueira, R. G., Prabhakaran, S., Mishra, N. K., Beaman, C. B., Hinman, J. D., et al. (2022) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.121.000201 · Cited by 3
Clopidogrel: What Is a Cardiologist to Do?
Ford, N. F. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.330 · Cited by 3
Antiplatelet Efficacy of Fixed-Dose Aspirin–Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation
Lim, S., Kim, P. J., Baek, C., Kim, T., Koh, Y. S., Park, H., Kim, H.-Y., Chang, K., Chung, W. S., & Seung, K. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0350-2 · Cited by 3
Monitoring and Reversal of Anticoagulation and Antiplatelets
Yost, G. W., & Steinhubl, S. R. (2013) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2013.05.008 · Cited by 3
The future of inpatient anticoagulation management
Burnett, A., & Trujillo, T. C. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0892-1 · Cited by 3
An emerging consensus
Leipziger, D. (2017) · Routledge eBooks · doi:10.4324/9781351278881-40 · Cited by 3
Prevalence of high on-treatment platelet reactivity in patients after percutaneous coronary intervention
Avramović, D., Kovacevic, V., Milic, N. M., Ristić, A. D., Ostojić, M., & Beleslin, B. (2016) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2016.05.006 · Cited by 3
Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction
Harari, R., & Baber, U. (2016) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2016.06.007 · Cited by 3
Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients
Kukuła, K., Kłopotowski, M. M., Kunicki, P. K., Jamiołkowski, J., Dębski, A., Bekta, P., Chmielak, Z., & Witkowski, A. (2016) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000614 · Cited by 3
Optimal platelet function test for in-stent tissue protrusion following carotid artery stenting
Tsujimoto, M., Enomoto, Y., Miyai, M., Egashira, Y., & Iwama, T. (2018) · Journal of International Medical Research · doi:10.1177/0300060518762949 · Cited by 3
High On-Treatment Platelet Reactivity Determinants on Dual Antiplatelet Therapy in Patients With Ischemic Heart Disease Before Elective Percutaneous Coronary Intervention
Golukhova, E. Z., Grigoryan, M. V., Николаевна, Р. М., & Bulaeva, N. I. (2018) · Kardiologiia · doi:10.18087/cardio.2018.4.10104 · Cited by 3
A meta‐analysis of efficacy and safety of genotype‐guided versus standard of care treatment strategies in selecting antiplatelet therapy in patients with acute coronary syndrome
Nazir, S., Ahuja, K. R., Virk, H. U. H., Elzanaty, A., Waheed, T. A., Changal, K., Wohlfarth, K. M., Lakhter, V., Grande, R., & Eltahawy, E. A. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28860 · Cited by 3
Point-of-Care Platelet Function Tests
Casso, G., Lanzi, F., & Marcucci, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-55004-1_4 · Cited by 3
Platelet Function Testing for Cardiac Surgery Patients on Antiplatelet Therapy: The Extreme Variability of Point-Of-Care Tests
Ondondo, B. (2018) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1412 · Cited by 3
Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial
Lee, W., Suh, J., Park, J. J., Yoon, C., Cho, Y., Youn, T., & Chae, I. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0938-6 · Cited by 3
Clopidogrel Resistance
Jeong, Y. (2013) · Korean Journal of Medicine · doi:10.3904/kjm.2013.85.1.1 · Cited by 3
Treating lacunar strokes occurring on aspirin
Castilla‐Guerra, L., & Sacco, R. L. (2014) · Neurology · doi:10.1212/wnl.0000000000000092 · Cited by 3
Use of antiplatelet drugs in stroke prevention: time for a rethink?
Loke, Y. K., White, J. R., Bettencourt‐Silva, J. H., Potter, J. F., & Myint, P. K. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-131446 · Cited by 3
Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial
Messas, N., Tanguay, J., & Lordkipanidzé, M. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.04.46 · Cited by 3
Does Platelet Reactivity Testing Predict Post-Operative Bleeding Risk?
Bittl, J. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.016 · Cited by 3
Platelet Function Testing Is Required for Intracranial Stent Placement
Chapot, R. (2021) · Stroke · doi:10.1161/strokeaha.121.036457 · Cited by 3
Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry
Kang, J., Park, S., Park, K. W., Joo, H. J., Chang, K., Park, Y., Song, Y. B., Ahn, S. G., Suh, J., Lee, S. Y., et al. (2025) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.125.015737 · Cited by 2
MicroRNA dynamics and their link to platelet function following acute ST-segment elevation myocardial infarction
Pedersen, O. B., Grove, E. L., Kristensen, S. D., Pasalic, L., Hvas, A., & Nissen, P. H. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109518 · Cited by 2
Antiplatelet Therapy
Amison, R. T., & Pitchford, S. C. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2025_784 · Cited by 2
ARCTIC leaves platelet testing out in the cold
Lim, G. B. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.165 · Cited by 2
Platelet reactivity after coronary stenting
Price, M. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61542-1 · Cited by 2
Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention
Bhatty, S., Ali, A., Shetty, R., Sumption, K. F., Cowley, M. J., & Jovin, I. S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.901149 · Cited by 2
Novel antithrombotic agents 2 Clinical evidence for oral antiplatelet therapy in acute coronary syndromes
Wiviott, S. D., & Steg, P. G. (2015) · Cited by 2
Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study
Deharo, P., Quilici, J., Bonnet, G., Grosdidier, C., Morange, P., Alessi, M., Bonnet, J.-L., & Cuisset, T. (2016) · Platelets · doi:10.1080/09537104.2016.1190006 · Cited by 2
Self-citation
Multiple Genetic Mutations Increase the Risk of Thrombosis Associated With Clopidogrel After Percutaneous Coronary Intervention
Jin, H., Song, J., Shen, X., Liang, Q., Sun, G., & Yu, Y. (2023) · Pharmacogenomics · doi:10.2217/pgs-2022-0167 · Cited by 2
Dynamic perioperative platelet activity and cardiovascular events in peripheral artery disease
Kennedy, N. N., Xia, Y., Barrett, T. J., Luttrell-Williams, E. S., Berland, T. L., Cayne, N. S., Garg, K., Jacobowitz, G. R., Lamparello, P. J., Maldonado, T. S., et al. (2024) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2024.09.028 · Cited by 2
Clopidogrel Response Variability: Etiology and Clinical Relevance
Bonello, L., Gaubert, M., Laine, M., Barragan, P. T., Pinto, J., Iloud, A., Lemesle, G., Roch, A., Dignat‐George, F., Paganelli, F. F., et al. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0437-6 · Cited by 2
Antiplatelet therapy after PCI in patients with high risk of bleeding
Zheleva, I., & Гелев, В. (2020) · Pharmacia · doi:10.3897/pharmacia.67.e52737 · Cited by 2
Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Camaj, A., Miller, M. S., Halperin, J. L., & Giustino, G. (2020) · Cardiology Clinics · doi:10.1016/j.ccl.2020.07.006 · Cited by 2
Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials
Madhavan, M. V., Bikdeli, B., Redfors, B., Biondi‐Zoccai, G., Varunok, N., Burton, J., Crowley, A., Francese, D. P., Gupta, A., Der-Nigoghossian, C. A., et al. (2020) · Minerva Cardiology and Angiology · doi:10.23736/s0026-4725.20.05353-0 · Cited by 2
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome
Santana‐Mateos, M., Medina-Gil, J. M., Saavedra, P., Martínez‐Quintana, E., Rodríguez‐González, F., & Tugores, A. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2016 · Cited by 2
Current antiplatelet agents: place in therapy and role of genetic testing
Yang, E. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1195-5 · Cited by 2
Pharmacogenomics in Interventional Pharmacology
Barrett, P. M., & Price, M. J. (2013) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2013.05.006 · Cited by 2
Impacto de CYP2C19*2 en la reactividad plaquetar en pacientes con síndrome coronario agudo tratados con clopidogrel
Cano, P., Consuegra‐Sánchez, L., Conesa‐Zamora, P., Torres‐Moreno, D., Jaulent, L., Villareal, D. D., Picó, F., & Villegas, M. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.04.042 · Cited by 2
Point of Care Testing
Weber, C. F., Zacharowski, K. D., & Jámbor, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54953-3_23 · Cited by 2
P2Y12 Antagonists: Pharmacology, Efficacy and Patient Considerations
Shameem, R., Hamid, M. S., Randhawa, A., Spaccavento, C., & Garatt, K. (2014) · Cited by 2
New Insights for Low Dosing With the New P2Y12 Inhibitors
Silvain, J., Kernéis, M., Collet, J., Montalescot, G., & for the ACTION Study Group (2014) · Circulation Journal · doi:10.1253/circj.cj-14-1166 · Cited by 2
Self-citation
General Aspects of Platelet Function Tests
Paniccia, R., Martínez, B., Haxhiademi, D., & Prisco, D. (2015) · Springer eBooks · doi:10.1007/978-3-319-24795-3_3 · Cited by 2
Pharmacogenomics of Clopidogrel
Giusti, B., Saracini, C., Galora, S., & Marcucci, R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00025-6 · Cited by 2
TIMELINE FOR THE DOUBLE ANTIPLATELET THERAPY. FACTS AND SUGGESTIONS
Барбараш, О. Л., & Кашталап, В. В. (2016) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2016-2-75-83 · Cited by 2
Assessing strategies to improve patient management
Waksman, R. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.210 · Cited by 2
Intralesional delivery of glycoprotein IIb / IIIa inhibitors in acute myocardial infarction: Review and recommendations
Kirresh, A. Z., Candilio, L., & Stone, G. W. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.30008 · Cited by 2
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
Berteotti, M., Gori, A. M., Giusti, B., Fortini, A., Grossi, G., Ciardetti, N., Migliorini, A., Lotti, E., Valenti, R., Mario, C. D., et al. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02784-z · Cited by 2
Predictors of successful acetylsalicylic acid resistance suppression after percutaneous coronary revascularisation
Dominiak, M., Wcisło, T., Krzemińska‐Pakuła, M., Bednarkiewicz, Z., Figiel, Ł., & Kasprzak, J. D. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0323 · Cited by 2
Outline of “Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH”
Tomiyama, Y. (2016) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.27.365 · Cited by 2
Antiplatelet and Anticoagulant Drugs
Ducrocq, G., & Steg, P. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00021-2 · Cited by 2
Carotid and Intracranial Stent Placement
Moore, B., Taylor, R. A., Nguyen, C., & Smith, M. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-32106-8.00034-0 · Cited by 2
An Observational Study of the Relationship Between Outcome and Platelet Reactivity in Chinese Patients Undergoing PCI Loading with 600 mg Clopidogrel
Li, J., Weng, L., Li, X., Li, Y., Yan, S., Song, Z. Y., Zhang, X., Cha, L., Lin, L., Yang, T., et al. (2020) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2019.0580 · Cited by 2
Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy
Nardin, M., Verdoia, M., Gioscia, R., Negro, F., & Luca, G. D. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.12.004 · Cited by 2
Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function
Dang, W., Wang, J., Zhang, Q., Liu, N., Li, W., & Yao, Z. (2021) · Medicine · doi:10.1097/md.0000000000025601 · Cited by 2
Switching from clopidogrel to prasugrel or ticagrelor: tips and tricks
Cattaneo, M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw103 · Cited by 2
Current status of personalized medicine based on pharmacogenetics in cardiovascular medicine
Tomlinson, B., Hu, M., Waye, M. M. Y., Chan, P., & Liu, Z.-M. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1142826 · Cited by 2
Is there a ‘therapeutic window’ for antiplatelet therapy?
Ayabe, K., & Goto, S. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw033 · Cited by 2
Monitoring Platelet Function in Children With Ventricular Assist Devices: The Devil Is in the Details
Massicotte, M. P., & Kreuziger, L. B. (2019) · ASAIO Journal · doi:10.1097/mat.0000000000000948 · Cited by 1
Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Rajachandran, M. S., & Lange, R. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02071-0 · Cited by 1

Authors: Collet, J.-P., Cuisset, T., Rangé, G., Cayla, G., Elhadad, S., Pouillot, C., Henry, P., Motreff, P., Carrié, D., Boueri, Z., Belle, L., Van Belle, E., Rousseau, H., Aubry, P., Monségu, J., Sabouret, P., O'Connor, S. A., Abtan, J., Kerneis, M., Saint-Etienne, C., Barthélémy, O., Beygui, F., Silvain, J., Vicaut, E., & Montalescot, G.
Affiliations: Pitié-Salpêtrière Hospital (FR)
Hôpital de la Timone (FR)
Les Hôpitaux de Chartres (FR)
Centre Hospitalier Universitaire de Nîmes (FR)
Hôpital Lariboisière (FR)
Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
Hôpital Rangueil (FR)
Hôpital Bichat-Claude-Bernard (FR)
HIA du Val-de-Grâce à Paris (FR)
ORCID: Collet, Jean-Philippe
Cuisset, Thomas
Rangé, Grégoire
Cayla, Guillaume
Elhadad, Simon
Pouillot, Christophe
Henry, Patrick
Motreff, Pascal
Carrié, Didier
Rousseau, Hélène
Aubry, Pierre
Sabouret, Pierre
Abtan, Jérémie
Barthélémy, Olivier
Beygui, Farzin
Silvain, Johanne
Montalescot, Gilles
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-11-29
Volume: 367
Issue: 22
Pages: 2100-2109
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1209979
OpenAlex: W2145323902
Cited by: 887
References: 26
Citations by year: 2026: 15 · 2025: 20 · 2024: 22 · 2023: 31 · 2022: 31 · 2021: 47 · 2020: 44 · 2019: 52 · 2018: 72 · 2017: 77 · 2016: 80 · 2015: 123 · 2014: 122 · 2013: 141 · 2012: 8
FWCI: 81.10
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: antiplatelet therapy, coronary stenting, platelet function monitoring, VerifyNow P2Y12 assay, clopidogrel, prasugrel, aspirin, stent thrombosis, bleeding events, glycoprotein IIb/IIIa inhibitors, individualized dosing, major adverse cardiovascular events
MeSH terms: Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Coronary Disease, Coronary Thrombosis, Female, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Pyridines, Thiophenes, Ticlopidine, Stents, Drug Monitoring, Point-of-Care Systems, Retreatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks